The concept of chronic obstructive pulmonary disease clinical control as a decision - making tool in real clinical practice for optimizing of basic pharmacotherapy


Cite item

Full Text

Abstract

The main goals of COPD therapy are to achieve clinical stability with minimal clinical manifestations and low risk of relapse. The proposed COPD control concept by analogy with asthma has not been quite well characterized yet. COPD control is defined as "the long - term maintenance of a clinical situation with a low impact of symptoms on the patient’s life and absence of exacerbations." The situation of clinical control in COPD is considered desirable and potentially achievable for most patients with COPD. Pharmacotherapeutic options for COPD are constantly expanding. The control concept may be useful when the decision on treatment of COPD is made for dynamic adjustment of the therapy volume.

About the authors

S N Avdeev

I.M. Sechenov First Moscow State Medical University (Sechenovskiy University)

член-корр. РАН, д.м.н., проф., зав. каф. пульмонологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет) Минздрава России, зав. клиническим отд. ФГБУ «НИИ пульмонологии» ФМБА России; ORCID: 0000-0002-5999-2150 Moscow, Russia

Z R Aisanov

N.I. Pirogov Russian State National Research Medical University

д.м.н., проф. каф пульмонологии ФДПО ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России; ORCID: 0000-0002-4044-674X Moscow, Russia

A S Belevsky

N.I. Pirogov Russian State National Research Medical University

д.м.н., проф., зав. каф. пульмонологии ФДПО ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России; ORCID: 0000-0001-6050-724X Moscow, Russia

K M Beeh

Insaf Respiratory Research Institute

д.м.н., проф., медицинский директор института респираторных исследований Insaf; ORCID: 0000-0001-9067-118X Wiesbaden, Germany

A A Vizel

Kazan State Medical University

д.м.н., проф., зав. каф. фтизиопульмонологии Казанского государственного медицинского университета; ORCID: 0000-0001-5028-5276 Kazan, Russia

S K Zyryanov

Peoples' Friendship University of Russia

д.м.н., проф., зав. каф. общей и клинической фармакологии Российского университета дружбы народов; ORCID: 0000-0003-2592-9695 Moscow, Russia

G L Ignatova

South Ural State Medical University

д.м.н., проф., зав. каф. терапии института дополнительного профессионального образования ФГБОУ ВО «ЮУГМУ» Минздрава России; ORCID: 0000-0002-0877-6554 Chelyabinsk, Russia

K Kostikas

University of Ioannina School of Medicine

к.м.н., доцент, зав. каф. респираторной медицины Университетской клиники Янины; ORCID: 0000-0003-0774-3942 Ioannina, Greece

I V Leshchenko

Ural State Medical University

д.м.н., проф. каф. фтизиатрии, пульмонологии и торакальной хирургии ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России; ORCID: 0000-0002-1620-7159 Ekaterinburg, Russia

S I Ovcharenko

I.M. Sechenov First Moscow State Medical University (Sechenovskiy University)

Email: svetftk@mail.ru
д.м.н., проф., каф. факультетской терапии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет) Минздрава России; ORCID: 0000-0002-8254-6635 Moscow, Russia

A I Sinopal’nikov

Russian Medical Academy of Continuous Professional Education

д.м.н., проф., зав. каф. пульмонологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования»; ORCID: 0000-0002-1990-2042 Moscow, Russia

O N Titova

The 1 St. Petersburg Pavlov state medical university, Scientific research institute of pulmonology

д.м.н., проф., директор НИИ пульмонологии ФДПО ГБОУ ВПО «ПСПбГМУ им. акад. И.П. Павлова» Минздрава России; ORCID: 0000-0001-9645-360X Saint-Petersburg, Russia

E I Shmelev

Federal Central Research Institute of Tuberculosis

д.м.н., проф., зав. отд. дифференциальной диагностики ФГБНУ «Центральный НИИ туберкулеза»; ORCID: 0000-0002-1908-5601 Moscow, Russia

References

  1. Mc Donald V.M, Higgins I, Wood L.G, et al. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax. 2013;68:691-4. doi: 10.1136/thoraxjnl-2012-202646
  2. Soler-Cataluna J.J, Alczar-Navarrete B, Miravitlles M. The concept of control of COPD in clinical practice. Int J Chron Obstruct Pulmon Dis. 2014;9:1397-405. doi: 10.2147/COPD.S71370
  3. Soler-Cataluna J, Marzo M, Catalon P, Miralles C, Miravitlles M. Validation of clinical control in COPD as a new tool for optimizing treatment. Int J COPD. 2018:13:3719-31. doi: 10.2147/COPD.S178149
  4. Aisanov Z, Avdeev S, Arkhipov V, et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int J COPD. 2018;13:183-7. doi: 10.2147/COPD.S153770
  5. Miravitles M, Sliwinski P, Rhee C.K, et al. Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD. Respir Med. 2018;136:8-14. doi: 10.1016/ j.rmed.2018.01.019
  6. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. Available at: http://www.goldcopd.org/
  7. Rogliani P, Calzetta L, Braido F, et al. LABA/LAMA fixed - dose combinations in patients with COPD: a systematic review. Int J COPD. 2018;13:3115-30. doi: 10.2147/COPD.S170606
  8. Watz H, Troosters T, Beeh K.M, et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J COPD. 2017 Aug 24;12:2545-58. doi: 10.2147/COPD.S143488
  9. Hohlfeld J.M, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double - blind, randomised, crossover, placebo - controlled, single - centre trial. Lancet Respir Med. 2018 May;6(5):368-78. doi: 10.1016/S2213-2600(18)30054-7
  10. Calverley P, Anzueto A, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations DYNAGITO): a double - blind, randomised, parallel - group, active - controlled trial. Lancet Respir Med. 2018;6(5):337-44. doi: 10.1016/S2213-2600(18)30102-4
  11. Wedzicha J, Decramer M, Ficker J, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double - blind, parallel - group study. Lancet Respir Med. 2013;1:199-209. doi: 10.1016/S2213-2600(13)70115-2
  12. Wedzicha J.A, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016:374(9):2222-34. doi: 10.1056/NEJMoa1516385
  13. Anzueto A.C, Vogelmeier K, Kostikas K, et al. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. Int J COPD. 2017 May 4;12:1325-37. doi: 10.2147/COPD.S133307
  14. Namba Y, Togo S, Tulafu M. Combination of glycopyrronium and indacaterol inhibits carbachol - induced ERK5 signal in fibrotic processes. Respir Research. 2017;18(1):46. doi: 10.1186/s12931-017-0529-6
  15. Miravitlles M, Baek S, Vithlani V, et al. Optimal Bronchodilation for COPD Patients: Are All Long-Acting β₂-Agonist/Long-Acting Muscarinic Antagonists the Same? Tuberc Respir Dis. 2018;81:198-215. doi: 10.4046/trd.2018.0040
  16. Ferguson G, Rabe K, Martinez F, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co - suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double - blind, parallel - group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6:747-58. doi: 10.1016/S2213-2600(18)30327-8
  17. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double - blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076-84. doi: 10.1016/S0140-6736(18)30206-X
  18. Singh D, Agusti A, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: the GOLD science committee report 2019. Eur Respir J. 2019;53: (5).pii:1900164. doi: 10.1183/13993003.00164-2019
  19. Yun J, Lamb A, Chase R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;46:2037-47. doi: 10.1016/j.jaci.2018.04.010
  20. Avdeev S, Aisanov Z, Arkhipov V, et al. Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms. Int J COPD. 2019;14:1267-80. doi: 10.2147/COPD.S207775
  21. Contoli M, Pauletti A, Rossi M.R, et al. Long - term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur Respir J. 2017;50(4): 1700451. doi: 10.1183/13993003.00451-2017
  22. Horita N, Goto A, Shibata Y, et al. Long - acting muscarinic antagonist (LAMA) plus long - acting beta - agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable сhronic оbstructive рulmonary disease (COPD). Cochrane Database Syst Rev. 2017;(2). doi: 10.1002/ 14651858.CD012066 Pub 2
  23. Vogelmeier C.F, Criner G.J, Martinez F.J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Arch Broncoрneumol. 2017;53(3):128-49. doi: 10.1164/rccm.201701-0218PP
  24. Lipson D, Barnhart B, Brealey N, et al. Once-Daily Single - Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378:1671-80. doi: 10.1056/NEJMoa1713901
  25. Suissa S, Ariel A. Triple therapy trials in COPD: a precision medicine opportunity. ERJ. 2018;52:1801848. doi: 10.1183/13993003.01848-2018
  26. Vogelmeier C, Gaga M, Aalamian-Mattheis M, et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open - label randomised trial. Respir Res. 2017;18:140. doi: 10.11 86/s12931-017-0622-x
  27. Worth H, Buhl R, Criée C.P, et al. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study. Respir Med. 2017 Oct;131: 77-84. doi: 10.1016/j.rmed.2017.08.008
  28. Chapman K.R, Hurst J.R, Frent S.M, et al. Long-Term Triple Therapy De - escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. Am J Respir Crit Care Med. 2018;198(3):329-39. doi: 10.1164/rccm.201803-0405OC

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies